Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464228 · ClinicalTrials.gov registry record · Phase 2
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
A Phase 2 study of Relapsed or Refractory Peripheral T-Cell Lymphoma, sponsored by Kura Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 13
- Study locations
NCT02464228 is a Phase 2 study of Relapsed or Refractory Peripheral T-Cell Lymphoma that has completed, run by Kura Oncology. The registered enrollment target is 65 participants. The trial reports 13 study locations across 6 states.
The verdict
NCT02464228, a Phase 2 study of Relapsed or Refractory Peripheral T-Cell Lymphoma, has completed, sponsored by Kura Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 13
- Study locations
Study Summary
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.
Conditions Studied
Interventions
- DRUG Tipifarnib
Study Locations (13)
Other
- Samsung Medical Center - Seoul
- Hospital Universitari Vall d'Hebron - Barcelona
- Institut Catala d'Oncologia de Girona - Girona
- MD Anderson Cancer Center Madrid - Madrid
- Hospital Universitario 12 Octubre de Madrid - Madrid
- Hospital Universitario de Salamanca - Salamanca
- Hospital Universitario Virgen del Rocio - Seville
- Hospital Clinico Universitario de Valencia - Valencia
California
- Stanford University Medical Center - Palo Alto
Connecticut
- Yale University, Yale Cancer Center - New Haven
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc. - Tampa
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-02-25 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02464228
The ClinicalTrials.gov registry entry for NCT02464228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Tipifarnib is the first listed.
NCT02464228 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02464228 about?
NCT02464228 is a clinical study titled "Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy". Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.
What is the current status of trial NCT02464228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2016-02-25. Estimated completion is 2021-03-31.
What conditions does trial NCT02464228 study?
This clinical trial studies the following conditions: Relapsed or Refractory Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT02464228?
The interventions under investigation include: Tipifarnib (DRUG).
Who is sponsoring clinical trial NCT02464228?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02464228 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.